Target site modifications and efflux phenotype in clinical isolates of Streptococcus pneumoniae from Hong Kong with reduced susceptibility to fluoroquinolones

Journal of Antimicrobial Chemotherapy

Volumn 47, Issue 5, 2001, Pages 655-658

  Ho, P L ^a   Yam, W C ^c   Que, T L ^d   Tsang, D N C ^e   Seto, W H ^c   Ng, T K ^f   Ng, W S ^b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c QUEEN MARY HOSPITAL   (Hong Kong)

^d TUEN MUN HOSPITAL   (Hong Kong)

^e QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^f PRINCESS MARGARET HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; PENICILLIN G; PHENYLALANINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RESERPINE; SERINE; TROVAFLOXACIN;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG TARGETING; DRUG TRANSPORT; HONG KONG; MINIMUM INHIBITORY CONCENTRATION; MUTATION; NONHUMAN; PHENOTYPE; STREPTOCOCCUS PNEUMONIAE;

EID: 0035011959     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/47.5.655     Document Type: Article

References (9)

1. Ho, P. L., Que, T. L., Tsang, D. N., Ng, T. K., Chow, K. H. & Seto, W. H. (1999). Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrobial Agents and Chemotherapy 43, 1310-3.
2. National Committee for Clinical Laboratory Standards. (1999). Performance Standards for Antimicrobial Susceptibility Testing -Ninth Informational Supplement M100-S9. NCCLS, Villanova, PA.
3. Andrews, J. M., Ashby, J. P., Jevons, G. M. & Wise, R. (1999). Tentative minimum inhibitory concentration and zone diameter breakpoints for moxifloxacin using BSAC criteria. Journal of Antimicrobial Chemotherapy 44, 819-22.
4. Janoir, C., Zeller, V., Kitzis, M. D., Moreau, N. J. & Gutmann, L. (1996). High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrobial Agents and Chemotherapy 40, 2760-4.
5. Pan, X. S., Ambler, J., Mehtar, S. & Fisher, L. M. (1996). Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 40, 2321-6.
6. Jones, M. E., Sahm, D. F., Martin, N., Scheuring, S., Heisig, P., Thornsberry, C. et al. (2000). Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide survillance studies during the 1997-1998 respiratory season. Antimicrobial Agents and Chemotherapy 44, 462-6.
7. Broskey, J., Coleman, K., Gwynn, M. N., McCloskey, L., Traini, C., Voelker, L. et al. (2000). Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy 45, Suppl. 1, 95-9.
8. Perichon, B., Tankovic, J. & Courvalin, P. (1997). Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 41, 1166-7.
9. Beyer, R., Pestova, E., Millichap, J. J., Stosor, V., Noskin, G. A. & Peterson, L. R. (2000). A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux. Antimicrobial Agents and Chemotherapy 44, 798-801.